Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
TL;DR
Quantum BioPharma gains a competitive edge by appointing renowned MS expert Dr. Jack Antel to guide Lucid-MS into Phase 2 trials, accelerating development of their patented demyelination inhibitor.
Dr. Antel will design efficacy trials for Lucid-MS, Quantum BioPharma's investigational drug that inhibits demyelination in multiple sclerosis, as it advances into Phase 2 studies.
This appointment advances development of Lucid-MS, potentially improving treatment for multiple sclerosis patients by addressing the underlying mechanism of myelin degradation.
Quantum BioPharma adds Dr. Jack Antel, a Dystel Award-winning neurologist with 450+ publications, to their clinical advisory team alongside Dr. Peter Stys for MS drug development.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support development of Lucid-21-302, the company's patented investigational drug designed to inhibit demyelination in MS. Dr. Antel, a recipient of the National Multiple Sclerosis Society and American Academy of Neurology's Dystel Award with over 450 published articles, will guide the design of efficacy trials as Quantum advances Lucid-MS into Phase 2 studies.
The appointment of such a distinguished MS specialist signals Quantum BioPharma's commitment to rigorous clinical development for a condition affecting approximately 2.8 million people worldwide. Multiple sclerosis involves the immune system attacking the protective myelin sheath around nerve fibers, leading to communication problems between the brain and the rest of the body. Current treatments primarily focus on managing symptoms and reducing relapse rates, but none effectively address the underlying demyelination process that Lucid-MS targets.
Dr. Antel joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor, creating a formidable scientific advisory team for the MS program. This dual expertise in neurology and neuroscience positions Quantum BioPharma to potentially advance treatment beyond current standards of care. The company's focus on preventing and reversing myelin degradation represents a novel approach that could significantly impact how MS is treated if clinical trials prove successful.
Quantum BioPharma maintains additional business interests through its strategic investments and retains significant ownership in Unbuzzd Wellness Inc., though the Lucid-MS program represents the company's primary pharmaceutical development focus. Investors can access the latest news and updates relating to QNTM through the company's newsroom at https://ibn.fm/QNTM. The full press release detailing Dr. Antel's appointment is available at https://ibn.fm/NWMFj.
The progression of Lucid-MS into Phase 2 trials under Dr. Antel's guidance could have substantial implications for the MS treatment landscape. Successful development of a drug that directly addresses demyelination would represent a paradigm shift in MS management, potentially offering neuroprotective benefits beyond current immunomodulatory approaches. For the millions living with MS worldwide, this research direction offers hope for treatments that might not just slow disease progression but potentially reverse some of the neurological damage characteristic of the condition.
Curated from InvestorBrandNetwork (IBN)
